Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Published:2020-02 Issue: Volume:126 Page:33-44
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ascierto Paolo A.,Dummer Reinhard,Gogas Helen J.,Flaherty Keith T.,Arance Ana,Mandala Mario,Liszkay Gabriella,Garbe Claus,Schadendorf Dirk,Krajsova Ivana,Gutzmer Ralf,de Groot Jan Willem B.,Loquai Carmen,Gollerkeri Ashwin,Pickard Michael D.,Robert Caroline

Funder

Pfizer

Roche

Bristol-Myers Squibb

Merck Sharp & Dohme

Novartis

Amgen

Pierre Fabre

Amicus

Boehringer-Ingelheim

NeraCare

Philogen

Sanofi

Neracare

Array BioPharma

Boehringer Ingelheim

LEO Pharma

Hexal

InflaRx

Helsinn

GI Innovation

Immunocore

Incyte

Regeneron

4SC

AstraZeneca

Merck-EMD

Ultimovacs

Sun Pharma

Johnson&Johnson

Merck Serono

Servier

Biontech

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

2. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

3. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

4. Development of encorafenib for BRAF-mutated advanced melanoma;Koelblinger;Curr Opin Oncol,2018

5. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor;Stuart;Cancer Res,2012

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era;Child's Nervous System;2024-07-31

2. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

3. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma;European Journal of Cancer;2024-06

4. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy;The Oncologist;2024-05-20

5. Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report;Journal of Gastrointestinal Oncology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3